[go: up one dir, main page]

WO2009008489A1 - Antibody liposome - Google Patents

Antibody liposome Download PDF

Info

Publication number
WO2009008489A1
WO2009008489A1 PCT/JP2008/062526 JP2008062526W WO2009008489A1 WO 2009008489 A1 WO2009008489 A1 WO 2009008489A1 JP 2008062526 W JP2008062526 W JP 2008062526W WO 2009008489 A1 WO2009008489 A1 WO 2009008489A1
Authority
WO
WIPO (PCT)
Prior art keywords
liposome
antibody
bound
disclosed
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/062526
Other languages
French (fr)
Japanese (ja)
Inventor
Masahiko Hirai
Koichi Igarashi
Kazunori Oie
Takayuki Otani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katayama Chemical Industries Co Ltd
Original Assignee
Katayama Chemical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katayama Chemical Industries Co Ltd filed Critical Katayama Chemical Industries Co Ltd
Publication of WO2009008489A1 publication Critical patent/WO2009008489A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is an antibody-modified liposome. The antibody-modified liposome may comprise: (A) a liposome; (B) serum albumin bound to the liposome; (C) a spacer bound to serum albumin present on the surface of the liposome; and (D) an antibody bound to the spacer. Also disclosed are: a method for producing the antibody-modified liposome; and use of the antibody-modified liposome. Further disclosed are: a composition and a diagnosis method for diagnosing cancer or tumor; and a molecular imaging agent.
PCT/JP2008/062526 2007-07-10 2008-07-10 Antibody liposome Ceased WO2009008489A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007181556A JP2010215509A (en) 2007-07-10 2007-07-10 Antibody liposome
JP2007-181556 2007-07-10

Publications (1)

Publication Number Publication Date
WO2009008489A1 true WO2009008489A1 (en) 2009-01-15

Family

ID=40228660

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/062526 Ceased WO2009008489A1 (en) 2007-07-10 2008-07-10 Antibody liposome

Country Status (2)

Country Link
JP (1) JP2010215509A (en)
WO (1) WO2009008489A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133867A1 (en) * 2008-05-01 2009-11-05 片山化学工業株式会社 Liposome containing metal colloid
JP2010215572A (en) * 2009-03-17 2010-09-30 Japan Health Science Foundation Pulpitis diagnostic marker and pulpitis diagnostic system
WO2011128931A1 (en) * 2010-04-12 2011-10-20 財団法人ヒューマンサイエンス振興財団 Pulpitis diagnostic marker and pulpitis diagnostic system

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020189766A1 (en) * 2019-03-20 2020-09-24

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60501028A (en) * 1983-04-06 1985-07-04 サントル・ナシオナル・ドウ・ラ・ルシエルシユ・シアンテイフイク Method for detecting and measuring cell membrane protein-dependent cell endocytosis using fluorescence
JPS63106561A (en) * 1986-05-31 1988-05-11 Toshiba Corp Reagent for immunological analysis
WO2005011633A1 (en) * 2003-08-01 2005-02-10 National Institute Of Advanced Industrial Science And Technology Remedy or diagnostic for inflammatory disease containing target-directing liposome
JP2007031444A (en) * 2006-09-22 2007-02-08 National Institute Of Advanced Industrial & Technology Target-directed liposome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60501028A (en) * 1983-04-06 1985-07-04 サントル・ナシオナル・ドウ・ラ・ルシエルシユ・シアンテイフイク Method for detecting and measuring cell membrane protein-dependent cell endocytosis using fluorescence
JPS63106561A (en) * 1986-05-31 1988-05-11 Toshiba Corp Reagent for immunological analysis
WO2005011633A1 (en) * 2003-08-01 2005-02-10 National Institute Of Advanced Industrial Science And Technology Remedy or diagnostic for inflammatory disease containing target-directing liposome
JP2007031444A (en) * 2006-09-22 2007-02-08 National Institute Of Advanced Industrial & Technology Target-directed liposome

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HASHIMOTO Y.: "Yakubutsu Targeting to Monoclonal Antibody Shushoku Liposome", PHARMACIA, THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 21, no. 12, 1 December 1985 (1985-12-01), pages 1213 - 1216 *
HIRAI M. ET AL.: "Gekkan Medical Science Digest", NEW SCIENCE CO., LTD., vol. 33, no. 5, May 2007 (2007-05-01), pages 6 - 8 *
SUZUKI R. ET AL.: "Jisedaigata DDS Seizai to shite no Liposome no Kanosei", BIO. INDUSTRY, vol. 24, no. 3, March 2007 (2007-03-01), pages 51 - 60 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133867A1 (en) * 2008-05-01 2009-11-05 片山化学工業株式会社 Liposome containing metal colloid
JP2010215572A (en) * 2009-03-17 2010-09-30 Japan Health Science Foundation Pulpitis diagnostic marker and pulpitis diagnostic system
WO2011128931A1 (en) * 2010-04-12 2011-10-20 財団法人ヒューマンサイエンス振興財団 Pulpitis diagnostic marker and pulpitis diagnostic system

Also Published As

Publication number Publication date
JP2010215509A (en) 2010-09-30

Similar Documents

Publication Publication Date Title
WO2007106744A8 (en) Anti-5t4 antibodies and uses thereof
WO2004063387A3 (en) Fluorescent silica-based nanoparticles
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2009004822A1 (en) ANTI-Muc17 ANTIBODY
WO2009113814A3 (en) Protein marker for early diagnosis of liver cancer
WO2010027903A3 (en) Lung cancer diagnosis
WO2009058911A3 (en) Preparation and isolation of 5' capped mrna
WO2008052187A3 (en) Antibodies and immunoconjugates and uses therefor
WO2007146172A3 (en) Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
WO2007109376A3 (en) Anti-tumor cell antigen antibody therapeutics
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
WO2006130773A3 (en) Methods of treating brain tumors with antibodies
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2005055936A3 (en) Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
WO2008098917A3 (en) Novel antibodies against igf-ir
WO2007079284A3 (en) Lung cancer diagnostic assay
WO2009008489A1 (en) Antibody liposome
WO2008011710A8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
WO2005070456A3 (en) Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
WO2007022511A3 (en) Listeria-induced immunorecruitment and activation, and methods of use thereof
WO2008137733A3 (en) Micellar structures, methods of making micellar structures, methods of imaging, and methods of delivering agents
WO2007000320A3 (en) Method for diagnosing rheumatic diseases
WO2007107774A3 (en) Integrin alpha-10 subunit as therapeutic target and diagnostic/prognostic marker for cancer
EP1742654A4 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
WO2006074334A3 (en) Identification of rna targets using helicases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791074

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 08791074

Country of ref document: EP

Kind code of ref document: A1